Here at Bioxis, we have created biomaterial scaffolds that help regenerate tissues, improve patient outcomes, and provide better healthcare opportunities for doctors. We are focused on developing medical devices based on patented biomaterials technology with potentially accelerated pathways to market.

Our lead medical device candidate MTI-12 is currently at the pre-clinical stage for aesthetic indications; and our hyaluronic acid-based dermal filler brand, CYTOSIAL, has established into exclusive distribution agreements with distributors in Europe and Asia.